The present invention relates to metal complexes for use as pharmaceutical or veterinary agents for the treatment of multiple sclerosis. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions of this type include multiple sclerosis. The invention also relates to ligands useful in the preparation of metal complexes of this type.